IMVT-1402 Clinical Trials
6 recruitingDrug
Phase 25Phase 31
Showing 1–6 of 6 trials
Recruiting
Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH180 enrolled121 locationsNCT06979531
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Immunovant Sciences GmbH210 enrolled120 locationsNCT07018323
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled81 locationsNCT07039916
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Immunovant Sciences GmbH240 enrolled130 locationsNCT06727604
Recruiting
Phase 2
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH162 enrolled135 locationsNCT07032662
Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH56 enrolled86 locationsNCT06980805